Coherus BioSciences, Inc. reported a 4% increase in annual net revenue for 2024, reaching $267.0 million, driven by a 62% rise in UDENYCA® net revenue and a 29% increase in LOQTORZI® sales. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results